UK
-
Babylon Health’s CEO ‘Should Spend Some Time With Elizabeth Holmes’
U.K. doctor David Watkins has been a public critic of Babylon Health and its AI technology for years, during which has received anonymous emails from Babylon employees who shared his concerns but feared to speak out publicly. After Babylon collapsed, a former employee publicly declared that the AI engine was indeed faulty. As a longtime skeptic of Babylon’s claims surrounding its technology, Watkins said that Ali Parsa, the company’s CEO, shouldn’t be treated any differently to Elizabeth Holmes.
-
Quanta raises $245M, prepares to study in-home use of portable dialysis device
Quanta, a company making portable dialysis systems, raised $245 million in a series D funding round. The company plans to study its device for in-home use, after it was cleared last year to be used in hospital and post-acute care settings.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Startups, Telemedicine, Health Tech
Babylon continues buying spree with another California-based practice
Babylon Health bought two California-based medical practices as it charts a broader expansion across the U.S. But it’s still facing questions about the safety of its AI chatbot in the U.K., where the company is based.
-
Health organizations responding to Covid-19 at risk from state-backed hackers, cybersecurity officials say
Drugmakers, medical research groups and healthcare companies and organizations are at risk of “password spraying” attacks by state-sponsored hackers, the officials said in a joint statement.
-
AstraZeneca lung cancer drug, competitor to Roche, gets FDA nod
The drugmaker said Monday that the FDA had approved Imfinzi, its PD-L1 inhibitor, for first-line extensive-stage small cell lung cancer, with platinum chemotherapy. The drug creates a new competitive threat to Roche’s Tecentriq, which is approved for the same disease setting.
-
GSK, Immatics Biotechnologies enter $600M deal to develop T-cell therapies
The companies said Thursday that they would develop T-cell receptor therapies for cancers. Immatics, based in Germany, has several TCRs already in the clinic.
-
Geopolitical, economic concerns unlikely to stem pharma, life science industry capital deployment, report finds
Deal value for the third quarter fell sharply from what it was in the first and second quarter, but that was due to the absence of the large acquisitions that took place earlier this year rather than an overall downward trend.
-
Report: British drugmakers worry about damage to competitiveness after possible Brexit deal
In what was reported as an “unprecedented backlash,” trade groups representing U.K. drugmakers – as well as four other industries – for the first time expressed concerns about a possible Brexit deal, having previously been more concerned about a possible no-deal Brexit.
-
Another myeloma drug with same target as CAR-Ts shows successful Phase II results
Without providing details, GlaxoSmithKline said its trial of BCMA-targeting belantamab mafodotin was positive. The company plans to submit for regulatory approvals later this year – potentially ahead of bluebird and Celgene’s expected filing next year for the CAR-T bb2121.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
AstraZeneca immunotherapy combo flunks another lung cancer study
The company said Wednesday that the pairing of PD-L1 inhibitor Imfinzi and CTLA-4 inhibitor tremelimumab did not prolong overall survival in previously untreated metastatic non-small cell lung cancer. The Phase III results are the latest in a string of failures for the combination.
-
AstraZeneca’s immunotherapy drug scores key Phase III lung cancer win
The company said the Phase III CASPIAN study of Imfinzi in first-line, extensive-stage small-cell lung cancer was successful, but did not disclose further details. Roche’s Tecentriq is already approved for that indication, which accounts for two-thirds of SCLC cases.
-
AstraZeneca, Daiichi Sankyo’s $6.9B breast cancer drug partnership bears fruit in less than two months
The companies announced the partnership in March to develop trastuzumab deruxtecan, for which they plan to file approval later this year based on the successful Phase II study.
-
GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
-
Drugmakers partner with England’s NHS in $1.3B hepatitis C push
NHS said it hopes to make England the first country to eliminate HCV. The effort will involve finding people living with the virus and providing drugs procured from AbbVie, Gilead and Merck.
-
Artificial Intelligence, BioPharma
AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate
The in vivo molecule was discovered under a two-year-old partnership between the two companies to discovery drugs using artificial intelligence. It will be developed for COPD.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
